Statin Therapy
Statin use linked to lower risk for HCC, decompensation in chronic liver disease
Statins appeared to reduce the risk for hepatocellular carcinoma and hepatic decompensation among patients with chronic liver disease, according to findings in JAMA Internal Medicine.
Daily oral PCSK9 inhibitor cut LDL cholesterol by 50% over 12 weeks
CHICAGO — In a phase 2b study, treatment with a once-daily oral PCSK9 inhibitor added to statin therapy resulted in a more than 50% reduction in LDL cholesterol at 12 weeks in patients with hypercholesterolemia.
Breaking down barriers: How to optimize access, use of PCSK9 inhibitors
Over the years, there have been significant changes to the dyslipidemia medication management guidelines, alongside increasing evidence for novel cholesterol-lowering medications, including PCSK9 inhibitors.
Nurse-led behavior changes after heart attack cut subsequent event risk by 30%
CHICAGO — A nurse-coordinated intensive intervention program emphasizing lifestyle and behavioral changes after ACS was associated with a 30% reduction in major adverse CV events for patients, primarily driven by a reduction in nonfatal MI.
Q&A: ‘Normal’ blood glucose may still increase risk for heart disease
Slightly elevated blood glucose within a range of what is generally considered “normal” may be associated with increased risk for heart disease, researchers reported.
CAC score education may lower heart disease risk in people with a family history
Visualizing and explaining patients’ risk for coronary artery disease using coronary CT and coronary calcium scoring may improve statin adherence and subsequently lower risk for future CAD events, researchers reported.
AACE guidance examines medication options for preventing ASCVD in adults with dyslipidemia
Updated guidance on preventing atherosclerotic cardiovascular disease in people with dyslipidemia includes changes reflecting newer medications that could be added to statin therapy or used on patients intolerant to statins.
Wegovy may reduce need for antihypertensive, lipid-lowering therapies
Adults receiving semaglutide for the treatment of obesity were more likely to have antihypertensive or lipid-lowering therapy tapered or discontinued than those receiving placebo, according to data from the STEP trials.
Having three or more metabolic risk factors raises diabetes risk in people with HIV
In adults living with HIV, those with three or more metabolic risk factors had a higher risk for developing new-onset diabetes than those without any risk factors, according to new findings from the REPRIEVE trial.
Fruits and vegetables ‘foundational management’ for treating hypertension
Dietary acid reduction from fruits and vegetables or sodium bicarbonate improved kidney health in patients with hypertension and macroalbuminuria, findings from a randomized controlled trial showed.